Year |
Citation |
Score |
2020 |
Lipford JR, Cee V, Lanman B, Saiki A, Rex K, Volak L, Shimanovich R, Hinkle B. Abstract IA20: Unlocked groove—developing covalent inhibitors of KRASG12C Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-Ia20 |
0.309 |
|
2019 |
Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. Journal of Medicinal Chemistry. PMID 31820981 DOI: 10.2210/Pdb6Pgo/Pdb |
0.301 |
|
2019 |
Shin Y, Jeong JW, Wurz RP, Achanta P, Arvedson T, Bartberger MD, Campuzano IDG, Fucini R, Hansen SK, Ingersoll J, Iwig JS, Lipford JR, Ma V, Kopecky DJ, McCarter J, ... ... Lanman BA, et al. Discovery of -(1-Acryloylazetidin-3-yl)-2-(1-indol-1-yl)acetamides as Covalent Inhibitors of KRAS. Acs Medicinal Chemistry Letters. 10: 1302-1308. PMID 31531201 DOI: 10.1021/Acsmedchemlett.9B00258 |
0.316 |
|
2019 |
Wang HL, Andrews K, Booker SK, Canon J, Cee VJ, Chavez F, Chen Y, Eastwood H, Guerrero N, Herberich B, Hickman D, Lanman BA, Laszlo Iii J, Lee MR, Lipford JR, et al. Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim- 1/2 Kinase Inhibitor for Hematological Malignancies. Journal of Medicinal Chemistry. PMID 30624936 DOI: 10.1021/acs.jmedchem.8b01733 |
0.334 |
|
2019 |
Saiki AY, Gaida K, Rex K, Achanta P, Miguel TS, Koppada N, Bagal D, Lanman BA, Foti RS, McCarter JD, Volak LP, Canon J, Cee VJ, Lipford JR. Abstract 4484: Discovery and in vitro characterization of AMG 510–a potent and selective covalent small-molecule inhibitor of KRASG12C Cancer Research. 79: 4484-4484. DOI: 10.1158/1538-7445.Am2019-4484 |
0.318 |
|
2019 |
Lanman BA, Chen JJ, Liu L, Lopez P, Pickrell AJ, Reed AB, Wang H, Achanta P, Canon J, Erlanson DA, Fucini RV, Jeong JW, Mohr C, Saiki AY, Cee VJ, et al. Abstract 4455: Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12C for the treatment of solid tumors Cancer Research. 79: 4455-4455. DOI: 10.1158/1538-7445.Am2019-4455 |
0.32 |
|
2017 |
Lanman BA. Addressing supply issues for natural products in the clinic. Science (New York, N.Y.). 358: 166-167. PMID 29026028 DOI: 10.1126/Science.Aao5346 |
0.315 |
|
2016 |
Pettus LH, Andrews KL, Booker SK, Chen J, Cee VJ, Chavez F, Chen Y, Eastwood H, Guerrero N, Herberich BJ, Hickman D, Lanman BA, Laszlo Iii J, Lee MR, Lipford JR, et al. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable pan-Pim Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 27285051 DOI: 10.1021/Acs.Jmedchem.6B00610 |
0.314 |
|
2016 |
Cee VJ, Chavez F, Herberich B, Lanman BA, Pettus LH, Reed AB, Wu B, Wurz RP, Andrews KL, Chen J, Hickman D, Laszlo J, Lee MR, Guerrero N, Mattson BK, et al. Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors. Acs Medicinal Chemistry Letters. 7: 408-12. PMID 27096050 DOI: 10.1021/Acsmedchemlett.5B00403 |
0.314 |
|
2015 |
Wu B, Wang HL, Cee VJ, Lanman BA, Nixey T, Pettus L, Reed AB, Wurz RP, Guerrero N, Sastri C, Winston J, Lipford JR, Lee MR, Mohr C, Andrews KL, et al. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors. Bioorganic & Medicinal Chemistry Letters. 25: 775-80. PMID 25616902 DOI: 10.1016/J.Bmcl.2014.12.091 |
0.311 |
|
2015 |
Wurz RP, Pettus LH, Jackson C, Wu B, Wang HL, Herberich B, Cee V, Lanman BA, Reed AB, Chavez F, Nixey T, Laszlo J, Wang P, Nguyen Y, Sastri C, et al. The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 25: 847-55. PMID 25599837 DOI: 10.1016/J.Bmcl.2014.12.067 |
0.302 |
|
2015 |
Wang HL, Cee VJ, Chavez F, Lanman BA, Reed AB, Wu B, Guerrero N, Lipford JR, Sastri C, Winston J, Andrews KL, Huang X, Lee MR, Mohr C, Xu Y, et al. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 25: 834-40. PMID 25597005 DOI: 10.1016/J.Bmcl.2014.12.068 |
0.307 |
|
2014 |
Lanman BA, Reed AB, Cee VJ, Hong FT, Pettus LH, Wurz RP, Andrews KL, Jiang J, McCarter JD, Mullady EL, San Miguel T, Subramanian R, Wang L, Whittington DA, Wu T, et al. Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511. Bioorganic & Medicinal Chemistry Letters. 24: 5630-4. PMID 25466188 DOI: 10.1016/J.Bmcl.2014.10.085 |
0.361 |
|
2012 |
Norman MH, Andrews KL, Bo YY, Booker SK, Caenepeel S, Cee VJ, D'Angelo ND, Freeman DJ, Herberich BJ, Hong FT, Jackson CL, Jiang J, Lanman BA, Liu L, McCarter JD, et al. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511. Journal of Medicinal Chemistry. 55: 7796-816. PMID 22897589 DOI: 10.1021/Jm300846Z |
0.338 |
|
2012 |
Smith AL, D'Angelo ND, Bo YY, Booker SK, Cee VJ, Herberich B, Hong FT, Jackson CL, Lanman BA, Liu L, Nishimura N, Pettus LH, Reed AB, Tadesse S, Tamayo NA, et al. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases. Journal of Medicinal Chemistry. 55: 5188-219. PMID 22548365 DOI: 10.1021/Jm300184S |
0.306 |
|
2012 |
Reed AB, Lanman BA, Neira S, Harrington PE, Sham KK, Frohn M, Pickrell AJ, Tasker AS, Gore A, Fiorino M, Itano A, McElvain M, Middleton S, Morrison H, Xu H, et al. Isoform-selective thiazolo[5,4-b]pyridine S1P1 agonists possessing acyclic amino carboxylate head-groups. Bioorganic & Medicinal Chemistry Letters. 22: 1779-83. PMID 22257889 DOI: 10.1016/J.Bmcl.2011.12.073 |
0.341 |
|
2012 |
Frohn M, Cee VJ, Lanman BA, Pickrell AJ, Golden J, Rivenzon-Segal D, Middleton S, Fiorino M, Xu H, Schrag M, Xu Y, McElvain M, Muller K, Siu J, Bürli R. Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: potent S1P₠agonists with in vivo lymphocyte-depleting activity. Bioorganic & Medicinal Chemistry Letters. 22: 628-33. PMID 22100314 DOI: 10.1016/J.Bmcl.2011.10.069 |
0.313 |
|
2011 |
Pennington LD, Sham KK, Pickrell AJ, Harrington PE, Frohn MJ, Lanman BA, Reed AB, Croghan MD, Lee MR, Xu H, McElvain M, Xu Y, Zhang X, Fiorino M, Horner M, et al. 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. Acs Medicinal Chemistry Letters. 2: 752-7. PMID 24900263 DOI: 10.1021/Ml2001399 |
0.314 |
|
2007 |
Lanman BA, Overman LE, Paulini R, White NS. On the structure of palau'amine: evidence for the revised relative configuration from chemical synthesis. Journal of the American Chemical Society. 129: 12896-900. PMID 17902668 DOI: 10.1021/Ja074939X |
0.325 |
|
2006 |
Lanman BA, Overman LE. EVALUATION OF STRATEGIES FOR THE SYNTHESIS OF THE GUANIDINE HEMIAMINAL PORTION OF PALAU'AMINE. Heterocycles. 70: 557-570. PMID 19079749 DOI: 10.3987/Com-06-S(W)16 |
0.3 |
|
2004 |
Lanman BA, Myers AG. Efficient, stereoselective synthesis of trans-2,5-disubstituted morpholines. Organic Letters. 6: 1045-7. PMID 15012096 DOI: 10.1021/Ol049861T |
0.576 |
|
2002 |
Myers AG, Lanman BA. A solid-supported, enantioselective synthesis suitable for the rapid preparation of large numbers of diverse structural analogues of (-)-saframycin A. Journal of the American Chemical Society. 124: 12969-71. PMID 12405822 DOI: 10.1021/Ja027729N |
0.595 |
|
2000 |
Myers AG, Zhong B, Kung DW, Movassaghi M, Lanman BA, Kwon S. Synthesis of C-protected alpha-amino aldehydes of high enantiomeric excess from highly epimerizable N-protected alpha-amino aldehydes. Organic Letters. 2: 3337-40. PMID 11029204 DOI: 10.1021/Ol006427S |
0.58 |
|
2000 |
Myers AG, Zhong B, Movassaghi M, Kung DW, Lanman BA, Kwon S. Synthesis of highly epimerizable N-protected α-amino aldehydes of high enantiomeric excess Tetrahedron Letters. 41: 1359-1362. DOI: 10.1016/S0040-4039(99)02293-5 |
0.571 |
|
Show low-probability matches. |